  nab-Paclitaxel has demonstrated efficacy in adults with solid tumours and preclinical activity in paediatric solid tumour models. Results from phase I of a phase I/II study in paediatric patients with recurrent/refractory solid tumours treated with nab-paclitaxel are reported. Patients with recurrent/refractory extracranial solid tumours received nab-paclitaxel on days 1 , 8 and 15 every 4 weeks at 120 , 150 , 180 , 210 , 240 , or 270 mg/m Sixty-four patients were treated. Dose-limiting toxicities were grade 3 dizziness<symptom> at 120 mg/m nab-Paclitaxel 240 mg/m 2013-000144-26.